Search

Axsome Therapeutics Inc

Open

BrancheGesundheitswesen

204.51 -1.15

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

205

Max

207.95

Schlüsselkennzahlen

By Trading Economics

Einkommen

13M

-51M

Verkäufe

27M

218M

EPS

-0.99

Gewinnspanne

-23.498

Angestellte

1,346

EBITDA

11M

-50M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+40.06% upside

Dividenden

By Acuity

Nächstes Ergebnis

2. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

468M

11B

Vorheriger Eröffnungskurs

205.66

Vorheriger Schlusskurs

204.51

Nachrichtenstimmung

By Acuity

34%

66%

95 / 340 Ranking in Healthcare

Axsome Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

21. Aug. 2026, 19:41 UTC

Axsome Therapeutics Inc. shares are lower today, retracing from earlier gains and remaining below the 20-day moving average amid rising Treasury yields.

20. Aug. 2026, 20:01 UTC

Axsome Therapeutics Inc's shares are declining amid broader market pressures from Walmart's disappointing earnings, raising concerns about consumer spending.

17. Aug. 2026, 19:16 UTC

Axsome Therapeutics Inc shares are higher today, continuing an upward trend since Friday's close. No specific news was identified to explain the movement.

14. Aug. 2026, 19:36 UTC

Axsome Therapeutics Inc shares are higher today, rebounding from an earlier pullback, despite a broader market influenced by a decline in retail sales.

13. Aug. 2026, 19:56 UTC

Axsome Therapeutics Inc shares are declining, retracing from earlier session highs amid broader market trends and rising U.S. unemployment claims.

12. Aug. 2026, 22:36 UTC

Axsome Therapeutics shares higher in after-market trading, with no specific news identified. Broader market stability follows recent inflation data easing rate hike concerns.

11. Aug. 2026, 19:45 UTC

Social Media
News

Axsome Therapeutics shares are lower following a second-quarter loss of 99 cents per share, missing the consensus estimate of 83 cents.

10. Aug. 2026, 23:06 UTC

Axsome Therapeutics Inc shares are lower during after-market hours amid mixed market sentiment. The stock is trading below its 20-day moving average.

7. Aug. 2026, 19:52 UTC

Axsome Therapeutics Inc shares are higher during Friday's session, recovering from a brief dip after reaching a session high. No specific news was identified.

6. Aug. 2026, 23:01 UTC

Axsome Therapeutics Inc. is trading higher in after-market hours, showing stability despite no specific news. The stock remains below its 20-day moving average.

5. Aug. 2026, 19:36 UTC

Axsome Therapeutics Inc shares are lower, pulling back from earlier session highs. The stock remains significantly below its 20-day moving average.

4. Aug. 2026, 23:36 UTC

Axsome Therapeutics Inc shares are trading higher in after-market hours. Broader market dynamics may be influencing sentiment amid record highs in stock markets.

3. Aug. 2026, 22:16 UTC

Axsome Therapeutics Inc shares are higher in after-market hours, despite no specific news. The stock showed unusual activity amid broader market dynamics.

31. Juli 2026, 22:01 UTC

Axsome Therapeutics Inc shares are higher in after-market trading, reflecting strong interest despite no specific news. The stock remains below its 20-day moving average.

30. Juli 2026, 19:28 UTC

Axsome Therapeutics Inc is rising during Thursday's session, reversing four consecutive lower closes. The stock remains below its 20-day moving average.

29. Juli 2026, 22:01 UTC

Axsome Therapeutics Inc shares are lower in after-market trading, closing below their 20-day moving average amid broader market caution and geopolitical tensions.

28. Juli 2026, 19:51 UTC

Axsome Therapeutics Inc shares are lower today, breaking a trend of higher daily closes amid broader market declines, particularly in Asian markets.

27. Juli 2026, 20:14 UTC

Axsome Therapeutics Inc shares are lower in after-market hours, continuing a three-session trend. No specific news was identified to explain the movement.

24. Juli 2026, 23:51 UTC

Axsome Therapeutics Inc shares are lower in after-market hours, reflecting a notable decline since Friday's close, with no specific news identified.

22. Juli 2026, 19:11 UTC

Axsome Therapeutics Inc shares are trading higher during Wednesday's session, reaching a high earlier before pulling back slightly amid increased market volume.

21. Juli 2026, 19:51 UTC

Social Media
News

BMO Capital initiated coverage on Axsome Therapeutics with an Outperform rating and a $310 price target, contributing to a rise in shares today.

20. Juli 2026, 21:21 UTC

News

BMO Capital initiated coverage on Axsome Therapeutics with an Outperform rating and a $310 price target. Shares are trading higher in after-market hours.

Peer-Vergleich

Kursveränderung

Axsome Therapeutics Inc Prognose

Kursziel

By TipRanks

40.06% Vorteil

12-Monats-Prognose

Durchschnitt 291 USD  40.06%

Hoch 380 USD

Tief 251 USD

Basierend auf 13 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Axsome Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

13 ratings

12

Buy

1

Halten

0

Sell

Stimmung

By Acuity

95 / 340 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
help-icon Live chat